Electromyographic study of the arms in competitive karting senior category drivers / Estudio electromiográfico de los brazos en pilotos senior de karting de competición

The main goal of this cross-sectional study was to assess the muscular activity of the upper limbs in competitive kart drivers while driving in a closed karting circuit, using surface electromyography (EMGS). The most significant muscles of the upper limbs while driving were evaluated in thirteen drivers. Linear mixed models adjusted to a gamma distribution were used to evaluate differences in muscle activity based on the arm, number of laps, track characteristics, and kart type (with/without gears). Significant differences were found between muscle activity according to the type of kart (p <0.0001). Although changes were observed in the mean EMGS values, there were no significant differences between the laps of the circuit or the dominant arm. However, the results showed that there was a significant interaction between the type of kart and the dominant arm (p = 0.021). Muscle activity increased more significantly in the curves traced towards the dominant arms of the drivers (AU)

El objetivo del estudio transversal fue analizar la actividad muscular de las extremidades superiores en pilotos senior de karting de competición, mediante electromiografía de superficie (EMGS). Se evaluaron los músculos más significativos de las extremidades superiores durante la conducción en trece conductores. Se utilizaron modelos lineales mixtos ajustados a una distribución gamma para evaluar diferencias de actividad muscular en base al brazo, número de vueltas, características del trazado, y tipo de kart (con/sin marchas). Se encontraron diferencias significativas entre la actividad muscular según el tipo de kart (p<0,0001). Aunque se observaron cambios en los valores medios de EMGS, no hubo diferencias significativas entre las vueltas del circuito o el brazo dominante. Sin embargo, los resultados mostraron que hubo una interacción significativa entre el tipo de kart y el brazo dominante (p=0,021). La actividad muscular aumentó de manera más significativa en las curvas trazadas hacia el brazo dominante de los conductores (AU)

Long-term outcome predictors after functional remediation in patients with bipolar disorder.

BACKGROUND: Improving functioning in patients with bipolar disorder (BD) is one of the main objectives in clinical practice. Of the few psychosocial interventions that have been specifically developed to enhance the psychosocial outcome in BD, functional remediation (FR) is one which has demonstrated efficacy. The aim of this study was to examine which variables could predict improved functional outcome following the FR intervention in a sample of euthymic or subsyndromal patients with BD. METHODS: A total of 92 euthymic outpatients were included in this longitudinal study, with 62 completers. Partial correlations controlling for the functional outcome at baseline were calculated between demographic, clinical and neurocognitive variables, and functional outcome at endpoint was assessed by means of the Functioning Assessment Short Test scale. Next, a multiple regression analysis was run in order to identify potential predictors of functional outcome at 2-year follow-up, using the variables found to be statistically significant in the correlation analysis and other variables related to functioning as identified in the previous scientific literature. RESULTS: The regression model revealed that only two independent variables significantly contributed to the model (F(6,53): 4.003; p = 0.002), namely verbal memory and inhibitory control. The model accounted for 31.2% of the variance. No other demographic or clinical variable contributed to the model. CONCLUSIONS: Results suggest that patients with better cognitive performance at baseline, especially in terms of verbal memory and executive functions, may present better functional outcomes at long term follow-up after receiving functional remediation.

Consenso de expertos españoles sobre el uso de la safinamida en la enfermedad de Parkinson / Spanish expert consensus on the use of safinamide in Parkinson's disease

La safinamida es un nuevo fármaco para el tratamiento de pacientes con enfermedad de Parkinson (EP) con fluctuaciones como tratamiento complementario a levodopa. Dado que por el momento aún no existen estudios de fase IV postautorización debido a la reciente incorporación de la safinamida a la práctica clínica habitual, el interés de este proyecto radica en el desarrollo de una guía de manejo clínico de la safinamida basada en las opiniones de expertos de trastornos del movimiento. Este proyecto se desarrolló en 2 fases: una primera fase que constó de 16 reuniones locales y una segunda fase que consistió en una reunión nacional. Dichas reuniones siguieron un guion de trabajo preestablecido. Tras la reunión nacional se recopilaron las principales conclusiones de los expertos, que han supuesto la base para redactar la presente guía clínica. Se concluyó que la safinamida es eficaz en la reducción de las fluctuaciones motoras y no motoras. Los pacientes con EP con fluctuaciones leves-moderadas son los que más se benefician del tratamiento, si bien el fármaco puede contribuir a mejorar diversos problemas clínicos en pacientes con EP avanzada. Se ha destacado la posibilidad de reducir la dosis de otros fármacos dopaminérgicos tras la introducción de la safinamida, lo cual contribuiría a reducir efectos adversos como el trastorno de control de impulsos. Se hipotetizó sobre el posible efecto de la safinamida sobre la mejoría de las discinesias a dosis más altas de las habitualmente utilizadas. Se ha consensuado que la safinamida es bien tolerada y presenta un perfil de efectos adversos favorable frente a placebo. (AU)

Safinamide is a new add-on drug to levodopa for the treatment of Parkinson's disease (PD) with motor fluctuations. Due to the recent incorporation of safinamide into routine clinical practice, no post-authorisation phase IV studies on the safety of safinamide have been conducted to date. This study provides clinical management guidelines for safinamide based on the opinion of a group of experts in movement disorders. This project was developed in 2 phases: 16 local meetings in phase 1 and a national meeting in phase 2. The meetings followed a pre-established agenda. The present clinical practice guidelines are based on the main conclusions reached during the national meeting. The group concluded that safinamide is effective in reducing motor and non-motor fluctuations. PD patients with mild-to-moderate fluctuations benefit most from treatment, although the drug may also improve the clinical status of patients with advanced PD. The dose of other dopaminergic drugs may be reduced after introducing safinamide, which would contribute to reducing such adverse reactions as impulse control disorder. At doses higher than those usually prescribed, safinamide may also improve dyskinesia. The experts agreed that safinamide is well tolerated and causes few adverse reactions when compared with placebo. (AU)

Spanish expert consensus on the use of safinamide in Parkinson's disease.

Safinamide is a new add-on drug to levodopa for the treatment of Parkinson's disease (PD) with motor fluctuations. Due to the recent incorporation of safinamide into routine clinical practice, no post-authorisation phase IV studies on the safety of safinamide have been conducted to date. This study provides clinical management guidelines for safinamide based on the opinion of a group of experts in movement disorders. This project was developed in 2 phases: 16 local meetings in phase 1 and a national meeting in phase 2. The meetings followed a pre-established agenda. The present clinical practice guidelines are based on the main conclusions reached during the national meeting. The group concluded that safinamide is effective in reducing motor and non-motor fluctuations. PD patients with mild-to-moderate fluctuations benefit most from treatment, although the drug may also improve the clinical status of patients with advanced PD. The dose of other dopaminergic drugs may be reduced after introducing safinamide, which would contribute to reducing such adverse reactions as impulse control disorder. At doses higher than those usually prescribed, safinamide may also improve dyskinesia. The experts agreed that safinamide is well tolerated and causes few adverse reactions when compared with placebo.

Diseño de una prueba de equilibrio con características contextuales para adultos mayores / Design and validation of a balance test with context characteristics for older adults

Antecedentes La pérdida de equilibrio en los adultos mayores es multifactorial y aumenta el riesgo de caídas en esta población. Existen pruebas para evaluar el equilibrio, sin embargo, se centran en la evaluación de una sola tarea, en entornos estáticos, sin considerar las demandas del control postural en situaciones de la vida cotidiana, como la interacción de la persona con el contexto y las actividades multitarea. Objetivo Diseñar y validar una prueba de equilibrio para adultos mayores con características contextuales. Materiales y método Se desarrolló una metodología de recolección de datos mixta, con un diseño metodológico exploratorio secuencial DEXPLOX derivativo de un diseño de triangulación concurrente DITRIAC. Resultados Los resultados hallados en las primeras 3fases permitieron construir los ítems de la prueba de evaluación de equilibrio, luego se realizó la primera validación de expertos, con un coeficiente kappa de Fleiss de 0,4 y una validez de contenido de Lawshe de 0,95. La segunda validación por expertos dio como resultado en la validez facial una fuerza de concordancia interevaluadores excelente y una validez de contenido de Lawshe en relevancia de 0,95 y en pertinencia de 0,97. Conclusiones La prueba diseñada ha demostrado características de validez fuertes y puede ser aplicada en adultos mayores, pues se incluyen ítems que exigen respuestas somatosensoriales, como las que se realizan en las actividades de la vida diaria e ítems con actividades de doble tarea cognitivas en el contexto real (AU)

Background Balance impairment is multifactorial in older adults and increases risk of falls in this population. There are tests to evaluate balance; nevertheless, they are focused on the evaluation of a single task, in static environments, without representing postural control demands in everyday life situations, such as person interaction-context and multi-tasking activities. Objectives Design and validate a balance test with ecological validity for older adults. Materials and methods A mixed data collection methodology was developed, with an exploratory sequential DEXPLOX methodological design derived from a DITRIAC concurrent triangulation design. Results The results from the first 3phases permitted constructing the items of the balance assessment test to, then, conduct the first validation by experts, determining a Fleiss’ kappa of 0.4 and a Lawshe content validity ratio of 0.95. The second validation by experts yielded as a result in face validity an excellent strength of inter-rater agreement and a Lawshe content validity ratio of 0.95 in relevance and 0.97 in pertinence. Conclusions The test designed showed strong characteristics of ecological validity and can be applied to older adults, given that it includes items requiring somatosensory responses, like those performed in activities of daily living and items with cognitive dual task activities used in daily routines (AU)

[Design and validation of a balance test with context characteristics for older adults]. / Diseño de una prueba de equilibrio con características contextuales para adultos mayores.

BACKGROUND: Balance impairment is multifactorial in older adults and increases risk of falls in this population. There are tests to evaluate balance; nevertheless, they are focused on the evaluation of a single task, in static environments, without representing postural control demands in everyday life situations, such as person interaction-context and multi-tasking activities. OBJECTIVES: Design and validate a balance test with ecological validity for older adults. MATERIALS AND METHODS: A mixed data collection methodology was developed, with an exploratory sequential DEXPLOX methodological design derived from a DITRIAC concurrent triangulation design. RESULTS: The results from the first 3phases permitted constructing the items of the balance assessment test to, then, conduct the first validation by experts, determining a Fleiss' kappa of 0.4 and a Lawshe content validity ratio of 0.95. The second validation by experts yielded as a result in face validity an excellent strength of inter-rater agreement and a Lawshe content validity ratio of 0.95 in relevance and 0.97 in pertinence. CONCLUSIONS: The test designed showed strong characteristics of ecological validity and can be applied to older adults, given that it includes items requiring somatosensory responses, like those performed in activities of daily living and items with cognitive dual task activities used in daily routines.

Use of a mobile application for self-management of pancreatic enzyme replacement therapy is associated with improved gastro-intestinal related quality of life in children with Cystic Fibrosis.

BACKGROUND: Most patients with cystic fibrosis (CF) suffer from pancreatic insufficiency (PI), leading to fat malabsorption, malnutrition, abdominal discomfort and impaired growth. Pancreatic enzyme replacement therapy (PERT) is effective, but evidence based guidelines for dose adjustment are lacking. A mobile app for self-management of PERT was developed in the context of the HORIZON 2020 project MyCyFAPP. It contains an algorithm to calculate individual PERT-doses for optimal fat digestion, based on in vitro and in vivo studies carried out in the same project. In addition, the app includes a symptoms diary, educational material, and it is linked to a web tool allowing health care professionals to evaluate patient's data and provide feedback. METHODS: A 6-month open label prospective multicenter interventional clinical trial was performed to assess effects of using the app on gastro-intestinal related quality of life (GI QOL), measured by the CF-PedsQL-GI (shortened, CF specific version of the Pediatric Quality of Life Inventory, Gastrointestinal Symptoms Module). RESULTS: One hundred and seventy-one patients with CF and PI between 2 and 18 years were recruited at 6 European CF centers. Self-reported CF-PedsQL-GI improved significantly from month 0 (M0) (84.3, 76.4-90.3) to month 6 (M6) (89.4, 80.35-93.5) (p< 0.0001). Similar improvements were reported by parents. Lower baseline CF-PedsQL-GI was associated with a greater improvement at M6 (p < 0.001). CONCLUSIONS: The results suggest that the MyCyFAPP may improve GI QOL for children with CF. This tool may help patients to improve self-management of PERT, especially those with considerable GI symptoms.

Spanish expert consensus on the use of safinamide in Parkinson's disease. / Consenso de expertos españoles sobre el uso de la safinamida en la enfermedad de Parkinson.

Safinamide is a new add-on drug to levodopa for the treatment of Parkinson's disease (PD) with motor fluctuations. Due to the recent incorporation of safinamide into routine clinical practice, no post-authorisation phase IV studies on the safety of safinamide have been conducted to date. This study provides clinical management guidelines for safinamide based on the opinion of a group of experts in movement disorders. This project was developed in 2 phases: 16 local meetings in phase 1 and a national meeting in phase 2. The meetings followed a pre-established agenda. The present clinical practice guidelines are based on the main conclusions reached during the national meeting. The group concluded that safinamide is effective in reducing motor and non-motor fluctuations. PD patients with mild-to-moderate fluctuations benefit most from treatment, although the drug may also improve the clinical status of patients with advanced PD. The dose of other dopaminergic drugs may be reduced after introducing safinamide, which would contribute to reducing such adverse reactions as impulse control disorder. At doses higher than those usually prescribed, safinamide may also improve dyskinesia. The experts agreed that safinamide is well tolerated and causes few adverse reactions when compared with placebo.

Gender differences in C-reactive protein and homocysteine modulation of cognitive performance and real-world functioning in bipolar disorder.

BACKGROUND: Cognitive and psychosocial impairment has been associated with increased levels of C-reactive protein (CRP) and homocysteine in bipolar disorder, but gender differences have seldom been studied. METHODS: Two hundred and twenty-four bipolar outpatients were included. Cognitive performance was assessed through the Screen for Cognitive Impairment in Psychiatry (SCIP). Psychosocial functioning was evaluated using the Functioning Assessment Short Test (FAST) and the General Assessment of Functioning (GAF). Homocysteine and CRP levels were determined. Separate analyses were performed by gender. Partial correlations were calculated to test for associations between biomarkers and cognitive and psychosocial functioning. Hierarchical multiple regression was used to assess factors predicting cognitive and psychosocial functioning. Covariates were: age, education, duration of illness, hospital admissions, depressive symptoms, tobacco consumption, and BMI. RESULTS: A better performance was noted in women in delayed verbal learning (p = 0.010), along with better occupational functioning (p = 0.027) and greater leisure time impairment (p = 0.034). In men, CRP and homocysteine levels were associated with psychosocial dysfunction (interpersonal relationships and financial functioning, respectively). In women, CRP levels correlated with cognitive performance (SCIP total raw score, immediate and delayed verbal learning, and verbal fluency). CRP was a predictor of cognitive performance in women only. LIMITATIONS: The choice of the cognitive scale and covariates and the lack of a control group may be the main limitations. CONCLUSIONS: A gender difference was found in biomarker modulation of cognition and psychosocial functioning. A gender-based approach to cognition and real-world functioning should be considered in bipolar disorder to ensure an optimal outcome.

Thermal transport in epitaxial Si1-x Ge x alloy nanowires with varying composition and morphology.

We report on structural, compositional, and thermal characterization of self-assembled in-plane epitaxial Si1-x Ge x alloy nanowires grown by molecular beam epitaxy on Si (001) substrates. The thermal properties were studied by means of scanning thermal microscopy (SThM), while the microstructural characteristics, the spatial distribution of the elemental composition of the alloy nanowires and the sample surface were investigated by transmission electron microscopy and energy dispersive x-ray microanalysis. We provide new insights regarding the morphology of the in-plane nanostructures, their size-dependent gradient chemical composition, and the formation of a 5 nm thick wetting layer on the Si substrate surface. In addition, we directly probe heat transfer between a heated scanning probe sensor and Si1-x Ge x alloy nanowires of different morphological characteristics and we quantify their thermal resistance variations. We correlate the variations of the thermal signal to the dependence of the heat spreading with the cross-sectional geometry of the nanowires using finite element method simulations. With this method we determine the thermal conductivity of the nanowires with values in the range of 2-3 W m-1 K-1. These results provide valuable information in growth processes and show the great capability of the SThM technique in ambient environment for nanoscale thermal studies, otherwise not possible using conventional techniques.

Treatment of neurocognitive symptoms in unipolar depression: A systematic review and future perspectives.

BACKGROUND: Cognitive symptoms in Major Depressive Disorder (MDD) are persistent and commonly entail neurocognitive impairment and a decline in quality of life. This systematic review gathers the current scientific evidence on therapeutic strategies for neuropsychological impairment in MDD. METHOD: A systematic search on PubMed, PsycINFO and Clinicaltrials.gov was carried out on December 2016 according to PRISMA using Boolean terms to identify interventions for the treatment of cognitive dysfunction in MDD. Only English-written articles providing original data and focusing in adults with MDD were included with no time restrictions. RESULTS: A total of 95 studies reporting data on 40 pharmacological and non-pharmacological interventions were included. Interventions were grouped into the following categories: 1) Pharmacological Therapies (antidepressants, stimulants, compounds acting on NMDA receptors, compounds acting on the cholinergic system, compounds showing anti-inflammatory or antioxidant properties, other mechanisms of action), 2) Physical Therapies and 3) Psychological Therapies, 4) Exercise. There are some promising compounds showing a positive impact on cognitive symptoms including vortioxetine, lisdexamfetamine or erythropoietin. LIMITATIONS: The studies included showed significant methodological differences in heterogeneous samples. The lack of a standardized neuropsychological battery makes comparisons between studies difficult. CONCLUSION: Current evidence is not sufficient to widely recommend the use of procognitive treatments in MDD although promising results are coming to light.

Modelling the impact of water activity and fat content of dry-cured ham on the reduction of Salmonella enterica by high pressure processing.

This work aimed to quantify the impact of aw and fat content of dry-cured ham on the Log reduction of Salmonella enterica by high pressure (HP). Dry-cured ham with adjusted aw (0.86-0.96) and fat content (10-50%) was inoculated with S. enterica and pressurised (347-852MPa, 5min/15°C), following a Central Composite Design. Polynomial regression indicated a significant impact of pressure and aw on S. enterica HP-lethality. By lowering aw a clear piezoprotection was observed. At low aw (0.88) the S. enterica reduction was little affected by increasing pressure (e.g. 2.3 to 3.2 Logs at 450 to 750MPa, respectively). At the highest aw the estimated inactivation ranged from 3.3 to 8.9 Logs at 450 to 750MPa, respectively. No significant piezoprotective effect on S. enterica was recorded by the fat content. The relevance of food characteristics on the HP-lethality of S. enterica indicate the need to validate the HP effectiveness on the specific product.